Bausch Health

BHC

Market cap $2.35B

LAVAL, QC / ACCESS Newswire / November 24, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced the commencement of offers to exchange the Company's outstanding 4.875% Senior Secured Notes due 2028 (the "4.875% Notes") and 11.00% Senior Secured Notes due 2028 (the "11.00% Notes" and together with the 4.875% Notes, the "Existing Senior Secured Notes") for up to $1.6 billion aggregate principal amount (the "Maximum Notes Amount") of new 10.00% Senior Secured Notes due 2032 (the "New Notes" and, such offers, the "Offers") issued by 1261229 B.C. Ltd., the Company's indirect wholly-owned subsidiary (the "Issuer" and, together with the Company, the "Offerors"), in each case, pursuant to the terms described in a confidential exchange offer memorandum dated November 24, 2025 (the "Exchange Offer Memorandum").

Bausch (BHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

LAVAL, QC / ACCESS Newswire / November 18, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that Jean-Jacques Charhon, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida on December 2, 2025. A live audio webcast of the event will be accessible on the Investor Relations section of Bausch Health's website.

Bausch + Lomb CEO Brent Saunders joins 'Squawk Box' to preview the company's investor day, details of the company's three-year plan for profitable growth, impact of tariffs, and more.

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will outline the next chapter of its evolution today during an investor day event at the New York Stock Exchange. Leading Through Reinvention Over the past few years, Bausch + Lomb has undergone a complete transformation by redefining how it operates. The company has sharpened its focus through simplification, rebuilt its cultu.

Bausch Health (BHC) delivered a strong Q3, exceeding expectations and reinforcing the medium-term deleveraging investment thesis. BHC's upside potential is now 36.8%, with a Buy rating maintained and a fair value target of $9.1 per share (range $8-10). The core thesis centers on debt reduction, but significant risks remain, especially Xifaxan sales declines and refinancing challenges in 2027-2028.

Bausch Health (BHC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Expansion improves access to treatment options within periodontal care and helps strengthen partnerships with dental professionals within these populations. LAVAL, QC / ACCESS Newswire / November 5, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global diversified pharmaceutical company, and OraPharma, its dental products business, today announced the commercial expansion of OraPharma into Canada and Puerto Rico.

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will hold an investor day on Thursday, Nov. 13, 2025, at the New York Stock Exchange. Chairman and CEO Brent Saunders will provide an update on the company's transformation and strategic outlook, and Executive Vice President and Chief Financial Officer Sam Eldessouky will share details on a three-year plan to drive sustainable,.

Bausch Health Companies delivered strong Q3 results, with revenue up 6.8% year-over-year and EPS beating estimates by $0.10. BHC's growth is driven by successful product launches like Cabtreo, robust Xifaxan performance, and expansion in dermatology and aesthetics segments. The company raised guidance on adjusted EBITDA and operating cash flow, supported by cost management and strategic investments in R&D and AI optimization.